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In this study we aimed to estimate direct medical costs of Chronic Obstructive Pulmonary Disease (COPD) by
disease type; chronic bronchitis and emphysema.
This study estimates direct costs in 1996 dollars using a prevalence approach and both aggregate and micro-
costing.
A societal perspective is taken using prevalence, and multiple national, state and local data sources are used to
estimate health-care utilization and costs.
Chronic bronchitis and emphysema together account for $145 billion in annual direct costs. Inpatient costs are
greater than outpatient and emergency costs ($83 vs. $78 billion) and hospital and medication costs account for
most resources spent. The high prevalence of chronic bronchitis accounts for its larger total costs ($117 billion)
compared with emphysema ($28 billion). Emphysema, which is more severe, has higher costs per prevalent case
($1341 vs. $816). Hospital stays account for the highest costs, $60 billion for chronic bronchitis and $19 billion for
emphysema. The hospitalization rate, length of stay and average cost per prevalent case are higher for emphysema
than for chronic bronchitis. Medication costs are the second highest cost category ($44 billion for chronic
bronchitis, $0693 billion for emphysema).
The high hospitalization and low home care costs (02% of total) suggest underuse of home care and room to
shift from acute to preventive care. More attention to healthcare management of chronic bronchitis and
emphysema is suggested, and improving inhaler and anti-smoking compliance might be important targets.
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Chronic Obstructive Pulmonary Disease (COPD), defines a
group of heterogeneous diseases characterized by chronic
airway obstruction, usually chronic bronchitis and emphy-
sema (1). It is a major cause of morbidity and mortality in
the United States and constitutes a significant cost burden
to society which will likely expand if the estimated 45%
increase in prevalence since 1982 continues (1). The ecient
allocation of resources in treating disease is a major focus
of managed care organizations in their disease management
process and economic studies can play an important role in
resource allocation decisions on a local and national basis.
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0954-6111/00/030204+10 $35?00/0diseases find resource allocation information of specific
diseases essential to ensure clinically useful and maximally
ecient treatments. Despite the significant cost burden of
obstructive lung diseases, there have been few studies of
disease specific cost and existing estimates are almost a
decade old (2–5). Most cost-of-illness studies examine costs
by broad disease categories with the goal of prioritizing
government allocation of resources among these broad
areas (2,3,6). For example, the cost burden of all
respiratory diseases in 1980 was $33 billion, $167 of which
were direct costs (2). As the delivery of healthcare becomes
more locally based within managed care organizations,
there is a need for resource allocation decisions based on
more specific disease states and costs.
Methods
DESIGN
This study estimates the annual direct medical costs of
COPD (specifically chronic bronchitis and emphysema) in
1996 in the United States using a prevalence approach, both
aggregate and micro-costing, and a societal perspective.# 2000 HARCOURT PUBLISHERS LTD
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data sources and published studies of prevalence and
treatment outcome. Estimates were made using Interna-
tional Classification of Disease version 9 (ICD-9) codes 490
and 491 for chronic bronchitis and ICD-9 492 for
emphysema (7). These ICD-9 groupings follow those of
the national health interview survey which is often used for
prevalence estimates and are consistent with the disease
classification in the other data sets used. Costs were
determined by stages or severity of disease based on
American Thoracic Society (ATS) criteria (1). If national
estimates were not available, San Francisco area charges
were used, deflating charges to cost with a cost to charge
ratio (8). These estimates were then inflated to 1996 US
dollars using the Consumer Price Index (CPI) inflation rates
for medical care (9). If no data were available (for
laboratory tests and medications), probabilities were
estimated by clinicians from constructed models of resource
use. This is standard practice in many disease specific
aggregate estimates of cost when other data are unavailable
(10–14).
DATA SOURCES
Prevalence and mortality
Prevalence of chronic bronchitis and emphysema was
estimated from the 1985 to 1994 National Health Interview
Surveys (NHIS) and applied to the 1996 population
estimates from the U.S. census reports (15–17) and
mortality was estimated from Center for Disease Control
(CDC) death certificates (17,18).
Direct costs
Categories of expenditures were inpatient care (hospital
stays and hospital inpatient doctor visits), outpatient care
(doctor visits, laboratory tests and medications), emergency
care and home and long-term care (home healthcare,
including equipment and supplies; and nursing home visits).
Inpatient care
Hospital discharges were determined from the 1993
National Hospital Discharge Survey (NHDS) (19). All
first-listed diagnosis stays (those determined at discharge to
be responsible for the hospital admission) and any of six
secondary diagnoses listed on the discharge abstract for
chronic bronchitis and emphysema were included to ensure
that COPD patients admitted for diagnoses other than
COPD, such as infections which are attributable to COPD,
are accounted for. For example, first listed diagnoses were
only 43% of all diagnoses for chronic bronchitis and only
15% of all diagnoses for emphysema patients hospitalized.
Including only first listed diagnoses would seriously under-
count hospital costs.
Hospital costs were obtained from charges in the
Healthcare Cost and Utilization Project (HCUP-3) (20).These charges were then reduced to costs using the
Medicare cost to charge ratio of 045. Hospital physician
visits were calculated using estimates based on the average
hospital length of stay for each disease. Costs for these
visits were obtained from the national Medicare physician
fee estimates in 1996 for an initial visit, a discharge visit,
and one standard visit per day during the remaining
hospitalization (21).
Outpatient care
All outpatient care was estimated based on the distribution
of prevalence by disease severity assuming 68–73% mild,
19% moderate and 8–13% severe disease (1). The annual
proportion of ambulatory physician visits included both
oce-based visits from the 1993 National Ambulatory
Medical Care Survey (NAMCS) and hospital outpatient
visits obtained from the National Hospital Ambulatory
Medical Care Survey: Outpatient Department (NHAMCS-
OP) (22,23). Costs were estimated using the average
national Medicare fee schedule for initial and return
physician visits.
The types of laboratory tests were estimated by disease
severity and included spirometry, pulse oximetry, chest
radiology and, for severe disease, arterial blood gases (1).
The frequency of each laboratory intervention was esti-
mated from the Canadian Thoracic Society Workshop
Group (8,24,25) and costs for each procedure were
estimated from a major medical center in San Francisco.
There were no other sources of data on laboratory tests so
these estimates are intended as a conservative estimate of
average laboratory test use in the COPD population and
although they represent only 34% of total costs, should be
further validated. Sensitivity analyses were done on selected
probabilities and cost estimates as well as to test assump-
tions about severity and compliance levels.
While several studies have estimated COPD costs (2,4,5)
no public use data are available on detailed medication
costs by disease. Annual drug costs were calculated by
disease severity using a micro-costing approach and
average wholesale price (26,27). Expert clinicians and
literature assessment of the recommended standards of
drug treatment for COPD by disease severity were used to
model a medication resource use profile of average practice
(1,24,28–32) (Table 3). The proportion of patients in each
severity category diered for chronic bronchitis and
emphysema patients respectively (mild: 73%, 68%; moder-
ate: 19%, 19%; and severe: 8%, 13%). The utilization of
drug treatment included vaccines, bronchodilators, anti-
biotics and steroids. Inhaler use was reduced by 50% based
on compliance results from the Lung Health Study (33).
Multidose Inhalers (MDIs) were the only delivery mode
included because of their predominant use in the outpatient
setting. Mucolytic agents were not included in the drug
treatment costs because they are not frequently utilized in
the U.S. We assumed that patients use bronchodilator
therapy throughout the course of their disease, with
theophylline added to the regimens for a proportion of
patients with moderate and severe disease and oral
206 L. WILSON ET AL.prednisone added to a proportion of those with severe
disease (Table 3). Studies suggest that only 20–30% of
patients with COPD improve when given chronic oral
steroid therapy and that there is yet no definitive way of
identifying the patients prior to treatment who will benefit
from this regimen. Furthermore, the side eect profiles of
steroids must be weighed against their potential benefit (34–
36). Because of these limitations, the use of prednisone was
applied to only one-fifth of the patients in the severe disease
category, and only for acute exacerbation (Table 3). In
addition, there may be a role for inhaled steroids in the
management of COPD. Inhaled steroids are currently being
evaluated and are sometimes used in clinical practice (1,34–
36). We therefore included inhaled corticosteroids for 20%
of patients in all severity categories used intermittently
(50% of the time annually). To further validate our
medication use profile we looked at the number of
prescriptions written for emphysema and chronic bronchitis
from the Scott and Levin Physicians Drug and Diagnosis
Audit (PDDA) which provides information on prescrip-
tions written in a staged sampling of about 3400 physicians
and is then weighted to the population (37).
Emergency care
The National Ambulatory Medical Care Survey: Emer-
gency Department (NAMCS:ED) 1993 was used to
determine utilization of emergency room visits. Estimates
were too low to be reliable for patients with emphysema, so
the emergency use rate for chronic bronchitis was used (38).
Costs per visit were calculated based on estimates of patient
severity and by the intensity of care by three levels of carePrevalence per 1000 Persons
ICD-9 Description 1985 1986 1987*
490, 491 Chronic Bronchitis 49.7 48.1 48.8
492 Emphysema 8.9 8.5 8.2
Total Total 58.6 56.6 57
*1987, 1991 estimated; Source: National Health Interview Surve
FIG 1. Prevalence of chronic bronchitis and emphysema (N
emphysema; –~–: total.(35% were level 1 intensity costs, 30% level 2 and 35% level
3) from a large medical center in California.
Home and institutional care
Home healthcare visits were determined using the National
Home and Hospice Care Survey (NHHCS) and the medical
equipment, supplies and services used were obtained from a
1990 report to the Senate Committee on Aging and updated
to 1996 (39,40). The medical equipment used in the home
included oxygen, a walker, a hospital bed, a bedside
commode and over-bed table.
The proportion of patients admitted to nursing homes
for the primary diagnoses of chronic bronchitis or
emphysema were obtained from the National Nursing
Home Survey (NNHS) for 1995 and updated to 1996 prices
(41). Medicare charges per day (reduced to costs) were used
to obtain total and per patient costs (42).
Results
PREVALENCE AND MORTALITY
The age and gender specific prevalence rates of chronic
bronchitis (54/1000) and emphysema (78/1000) were used
with age and sex specific census data to estimate the 1996
prevalence of 143 million cases of chronic bronchitis and
21 million cases of emphysema (8,9). The chronic
bronchitis prevalence rate per thousand has increased from
497 in 1985 to 54 in 1994 (Fig. 1), while the prevalence rate
for emphysema has decreased slightly from 89 to 78 cases1988 1989 1990 1991* 1992 1993 1994
49.4 49.2 51.1 52.4 53.7 54.3 54
7.9 8.2 8.2 7.9 7.6 7.6 7.8
57.3 57.4 59.3 60.3 6.3 61.9 61.8
y 1985-86, 1988-90, 1992-94.
umber per 1000 persons). –^ –: chronic bronchitis; –&–:
DIRECT MEDICAL COSTS OF COPD 207per thousand in that same time period. Taken together, the
prevalence of COPD is 164 million with a slight increase in
prevalence rate from 1985–1994, from 586 to 618 per
thousand persons, probably reflecting the general aging of
the population. The prevalence trends over time are the
same by gender except for emphysema where the prevalence
rate shows a slightly downward rate in males and a slightly
upward rate in females. These eects may be due to changes
in smoking habits of males (decreasing) and females
(increasing) since 1960 (17,18).
In 1996 there were an estimated 119 340 deaths (7.3 per
100 000 population) attributable as the underlying cause to
chronic bronchitis and emphysema, 2980 deaths from
chronic bronchitis (11/100 000) and substantially more,
116 360, from emphysema (62/100 000) (8,17). Although
the prevalence of chronic bronchitis is far greater than that
of emphysema, the latter disease exacts a greater annual
mortality. NCHS estimates of mortality from COPD are
somewhat higher (165 000 for 1996) than reported here, but
dier from ours in the exact diagnoses included (15).
Deaths from the Monthly Vital Statistics Report where the
ICD-9’s match ours closely report annual deaths (101 690)
close to ours for 1996 (4).TABLE 1. Direct medical care use and costs by disease and type
Frequency
(in thousands)
Chronic Bronchitis: ICD-9 #490,
#491, Base case
Total hospital inpatient care
Hospital stays 1 168 Discharges $
MD visits 5 840 Visits $
Total outpatient care
MD visits 11 473 Visits
Lab
Medications 14 325 Patients
Total emergency care 136 Admissions $1
Total home health care 21 Episodes $
Total nursing home 229 Admissions $2
Total direct costs for chronic bronchitis
Emphysema ICD-9 #492,
Base case
Total hospital inpatient care
Hospital stays 296 Discharges $
MD visits 1 480 Visits $
Total outpatient care
MD visits 529 Visits
Lab
Medications 2 069 Patients
Total emergency care 19 Admissions $1
Total home health care 10 Episodes $
Total nursing home 68 Admissions $2
Total direct costs for emphysema
Total direct costs for COPDDIRECT MEDICAL COSTS
The annual direct medical costs of COPD is $145 billion in
1996 dollars (Table 1). Total inpatient costs are $83 billion
(57% of total costs) while outpatient and emergency care
costs are $58 billion (40% of total costs), and home and
institutional care is only $034 billion. The largest costs are
for inpatient hospital stays ($78 billion) which are 54% of
total costs and medications ($51 billion) which are 35% of
the total costs. Laboratory costs account for only 34% and
outpatient physician visits account for only 17% of total
costs. Unlike the high emergency costs for asthma, the costs
of emergency room care are only 02% of the total costs for
COPD. Surprisingly, the costs of home healthcare and
nursing home care also account for only a small proportion
of total direct medical costs (23%).
When the COPD costs are analysed separately by disease
type, the higher disease prevalence of chronic bronchitis
and the greater relative severity of emphysema become
evident (Table 1). The annual direct medical cost of chronic
bronchitis is $117 billion, 42 times more than the total
costs for emphysema ($28 billion) which is 7 times less
prevalent. The average costs per prevalent case forof cost
Unit cost Total costs
(in millions)
Percent of
total
Cost per
prevalent case
$6322 542% $441
5101/Discharge $5958 510% $416
312/Discharge $364 31% $25
$5081 435% $351
$21/Visit $240 20% $17
$29/Patient $471 40% $33
$305/Patient $4370 37% $305
493/Admission $288 02% $201
8699/Episode $184 16% $13
340/Admission $557 0.5% $389
$11 671 100% $816
$1990 707% $962
6419/Discharge $1883 669% $910
361/Discharge $107 38% $52
$727 258% $346
$21/Visit $11 04% $6
$11/Patient $23 08% $11
$335/Patient $693 246% $335
493/Admission $40 01% $0
8 263/Episode $79 28% $38
340/Admission $166 06% $801
$2816 100% $1341
$14 492 $896
208 L. WILSON ET AL.emphysema are higher ($1341) than for chronic bronchitis
($816); 64% more, demonstrating the greater severity of
emphysema compared with chronic bronchitis.
Inpatient costs
Hospitalization stay costs were the highest cost category,
$78 billion overall, $60 billion for chronic bronchitis and
$19 billion for emphysema (Table 1). However, the average
hospitalization costs per admission are higher for emphy-
sema ($13 498) than for those with chronic bronchitis
($10 127). The hospitalization rate and length of stay (143
vs. 82 and 7.9 vs. 69 respectively) and the average cost per
prevalent case ($961 vs. $441) are higher for emphysema
than for chronic bronchitis (Table 2).
Outpatient costs
There are only 12 million physician visits annually for
patients with COPD cited as the main reason for the visit
(15 visits per prevalent case). The annual population
average is 54 visits per person for all causes (16,31).
Chronic bronchitis patients have visit costs 22 times that of
emphysema patients ($240. million vs. $11 million) (Table
1). The average physician visit costs per prevalent case are
also higher for chronic bronchitis than emphysema patients
($17 vs. $6) due to an annual visit rate of only 26/100
patients with emphysema. It may be that with the greater
intensity of emphysema, some physician visits are being
substituted with hospital visits or home care in these
patients. It also may be that COPD patients who visit their
physician are not coded with COPD as a reason for the visit
and therefore visits may be under-counted in the NAMCS
data base. However, physician visit costs are a small part of
the total costs and are varied in the sensitivity analysis as
discussed below.
Medication costs were the second highest cost category,
$44 billion for chronic bronchitis and $0.693 billion for
emphysema patients (Table 1). The literature does not
dierentiate between drugs used by patients with chronic
bronchitis and emphysema and therefore we use the same
drugs in our resource use profile for both diseases but vary
the proportion of patients in each severity category to
obtain dierent drug use and costs by disease. The annualTABLE 2. Hospital inpatient utilization and costs by disease 199
Disease No. of
discharges
(in thousands)1
Days of care
(in thousands)1,2
Length of
stay
(in days) 1
Hosp
ra
COPD 1465 10333 706
Chronic
Bronchitis
1168 8142 697
Emphysema 296 2396 792 1
1National Hospital Discharge Survey, 1993. Updated to 1996;
Management Information Corporation, (PMIC) 1996; 4Numbecost per prevalent case for COPD is $309 (Tables 1 and 3).
Costs by disease severity demonstrate that the majority of
total outpatient medication costs are for those 68–73% of
patients with mild disease ($2075 million). The 19% of
patients with moderate disease and 8–13% with severe
disease account for costs of $1809 million and $1098 million
in total medication costs. The per patient increases in costs
as disease severity increases are more than three times larger
from mild to moderate disease and increase 134 times from
moderate to severe disease. This is primarily because the
major cost drivers are the frequency of the use of the
ipratropium and albuterol inhalers. Mild patients were
given only intermittent use of inhalers, to reflect use about
50% of the time annually. The addition of theophylline and
prednisone which are added for treating acute disease, were
introduced into the market much earlier and do not add
much extra cost. Inhalers account for 84% of total
medication costs for COPD despite being included in the
model at only a 50% compliance rate, while other drugs
plus vaccines account for only 16% of costs. Inhalers
account for 100% of total medication costs for mild
disease, 86% for moderate disease and 82% for severe
disease. The cost of inhaled steroids amounts to only a
small amount of overall COPD drug costs (34% or $170
million).
Outpatient laboratory costs accounted for only $496
million, $471 million for chronic bronchitis, and $23 million
for emphysema. Those with severe disease account for 50%
of the visits and for about 53% of total laboratory test costs
in chronic bronchitis and only 48% in emphysema patients
(Table 1).
Emergency care
Emergency visit costs are also quite low, only 135 583 visits
and $288 million for chronic bronchitis patients and 18 623
visits and $40 million for emphysema patients. The overall
visit rate for COPD patients is only 09%.
Home and institutional care
Home health costs and nursing home costs account for only
18% of total costs. Annually, about 21 000 chronic
bronchitis (69%) and 9500 emphysema patients have some6, base case
italization
te1(%)
Total MD
visit costs
(in thousands)4($)
Total cost
including MD visits
(in billions)3, 4($)
Cost per
prevalent
case($)
893% 471 83 507
815% 363 63 441
43% 107 2.0 961
2Based on first-listed diagnosis; 3Physicians Fees. Practice
rs don’t add up due to rounding.
TABLE 3. COPD medication costs by drug and severity of disease (23,28–32,46,47)
No. Pts.
(in millions)
Total Costs Per Year
(in millions) ($)
Cost Per Patient ($)
A. Vaccines
Influenza Vaccine61 164 478 3
Pneumococcal Vaccine61 164 336 12
Total 814
B. Mild Disease (68–73% of Total) 119
Ipratropium MDI (12 pus day) 119 1026.6 86
Albuterol MDI Prn, (6 pus day) 119 6599 56
MDI Spacer61 119 2983 25
Beclomethasone, dble str., 1
5 of pts. 24 902 38
Total 119 2075 175
C. Moderate Disease (19% of Total) 31
Ipratropium MDI (12 pus day) 31 8086 260
Albuterol MDI (12 pus day) 31 6930 222
MDI Spacer 31 783 25
Theophylline (300mg BID) 1
4 of pts. 08 1708 219
10 day course of antibiotics 12 of pts. 16 110 7
Beclomethasone, dble str. 15 of pts. 06 474 76
Total 31 18091 584
D. Severe Disease (8–13% of Total)1 14
Ipratropium MDI (18 pus day) 14 5510 389
Albuterol MDI (12 pus day) 14 3148 222
MDI Spacer 14 356 25
Theophylline (300mg BID) 1
2 of pts 0.7 1552 219
10 day course of antibiotics 12 of pts 0.7 9.0 13
Prednisone 40 mg taper 15 pts 03 01 05
Beclomethasone, dble str. 15 of pts 03 323 114
Total 14 1098 784
Total Medication Costs 5064 309
DIRECT MEDICAL COSTS OF COPD 209home care and the total home care costs are $184 million
and $79 million respectively. The average cost per prevalent
case for home care across all patients is only $13 for chronic
bronchitis and is about three times higher ($38) for
emphysema. This suggests a low usage of home care by
these patients, only 02% for COPD overall. Only 18 per
10 000 patients with COPD have home care annually, 14
per 10 000 for chronic bronchitis patients and more (44 per
10 000) for emphysema patients.
Twenty-three thousand patients enter nursing homes
annually for chronic bronchitis (16 admits/10 000 patients),
and about 7000 enter due to emphysema (31 admits/10 000
patients), resulting in costs of $56 million and $17 million
respectively.
When the costs for chronic bronchitis are analysed
separately, the percentage of costs attributable to inpatient
hospital costs decreases from 57% for all COPD to 54%,
and increases to 71% for emphysema alone. Correspond-
ingly, total outpatient costs increase from 40% for all
COPD to 44% for chronic bronchitis alone and decrease to
only 26% for emphysema alone. As chronic bronchitis is a
chronic disease of moderate severity when compared toemphysema, it follows that the outpatient costs are greater.
Medication costs are 35% of total costs for COPD, 37%
for chronic bronchitis and only 25% for emphysema. Home
health costs for emphysema comprise 28% of emphysema
costs and 16% of chronic bronchitis costs as compared to
14% for home health costs for both diseases combined.
The relative increase in proportion of hospital inpatient
costs and home care costs for emphysema reflect the more
severe nature of this disease.
SENSITIVITY ANALYSES
We conducted sensitivity analyses on selected utilization
and cost parameters to account for uncertainties. We
estimated minimum and maximum case estimates using all
the lowest and highest parameter estimates together to
present the most extreme range (Table 4). We varied
estimates using two methods. Firstly, sampling errors using
standard error of estimates were calculated for national
data set estimates when available. Secondly, for non-
sampling errors, published ranges or clinically meaningful
210 L. WILSON ET AL.ranges when those were not available, were used to vary
parameters for the low and high cases.
NHIS data on prevalence are derived from a population
sample and therefore are subject to sampling error, as well
as to non-sampling error. We calculated approximate
standard errors (SE) of the prevalence rates of 0879 and
95% confidence intervals between 52 and 56 per 1000 for
chronic bronchitis and SE of 0334 and 95% confidence
intervals between 715 and 845 per 1000 for emphysema.
This results in a range of 1996 prevalence between 138 to
148 billion for chronic bronchitis and between 19 to 22
billion for emphysema. Changes in prevalence caused a
range in total costs from ($14.1–$152 billion).
Inpatient care
Hospitalization rates will vary depending on estimates of
the reason for the hospital admission between a minimum
where only first-listed diagnosis as reason for hospitaliza-
tion is selected, to a maximum when all admissions with
any listed diagnoses attributable to COPD are included.
Therefore we varied the number of NHIS hospital visits
included from the all-listed diagnoses data of the NHIS
from 25–75% of the diagnoses, which changed the
hospitalization rate from 698–1089% for COPD but more
than doubled the rate for emphysema patients (89%–
197%). Costs of total hospitalization ranged from $66–
104 billion for COPD; $51–74 billion for chronic
bronchitis, and from $12–27 billion for emphysema
(Table 4).
Outpatient care
Physician visits can also be aected by reason for visits and
thus were varied by increasing and decreasing the number
of visits by 25%. This change caused only a+1% change in
total outpatient care costs from the base case (Table 4).TABLE 4. Sensitivity ranges: total direct costs—1996
Base case
(costs in millions)
Total hospital inpatient costs 8312
Hospital stays 7841
Physician visits 471
Total outpatient care costs 5812
Physician visits 252
Labs 496
Medications 5064
Total emergency care costs 328
Total home health costs 263
Total nursing home costs 723
Total direct costs 14 492
($14.5 billion)
COPD: ICD-9 #490, #491, #492Changes in laboratory costs also had only a small eect on
total costs. We varied both the total number of visits and
the proportions of patient severity upon which we
estimated the number and extent of laboratory tests. The
range in total laboratory test costs was from $364 million to
$969 million for COPD.
Medication costs were already conservatively estimated
and thus the base case was also used for the low case
estimates. We varied the severity proportions from 8–16%
in the severe category of chronic bronchitis and from 13–
26% for emphysema at the expense of those with mild
disease. This resulted in an increase in intensity of
medication use and costs; from $51–59 billion ($44–51
billion for chronic bronchitis and from $693–855 million for
emphysema patients). Emergency department visits were
varied also by changing the proportion of disease severity.
These changes were small and varied emergency visit costs
from $269–355 million.
Home health and nursing home care
We varied the lengths of time patients received home
healthcare visits using the low and high ranges provided in
the data for home care visits. This caused a change in home
care costs per episode from $218–290. The total annual cost
per patient receiving home health care ranges from $7100–
9500, while the average cost per patient based on disease
prevalence ranges was low, from $13–18. The standard
error for nursing home visits was 995 with a 95%
confidence interval between 31 432 and 28 070 visits.
Because undercoding due to comorbidities is also a source
of error in nursing home costs, we varied them at a greater
rate than this sampling error variance. Nursing home costs
were varied by 25% in both directions and varied from
$542–904 million for both diseases. Table 4 summarizes
the eects of all the sensitivity analyses in a low and high
case. There is a 14–24% change from the base case to the
low and high cases, respectively.Low case
(costs in millions)
High case
(costs in millions)
6630 10 419
6270 9856
360 563
5617 7198
189 315
364 9686
5064 5914
269 355
218 290
542 904
12 546 18032
($12.5 billion) ($18.0 billion)
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This study demonstrates that chronic bronchitis and
emphysema are a significant cost burden to society, which
together accounted for $145 billion in direct costs in 1996.
Rice estimated that the costs of all respiratory diseases in
1980 accounted for $167 billion in direct costs ($43 billion
in costs when inflated to 1996), so these two diseases
account for 34% of this total (2). Another study of COPD
costs estimated $96 billion in direct care expenditures in
1991 ($126 billion in 1996 costs) (5). Our costs are higher
likely due to increasing disease prevalence, a more detailed
estimate of drug costs, and also the inclusion of a wider
range of causes for admission in determining hospital costs.
The major categories of cost are hospital stay costs ($74
billion) which are 54% of total costs and medications ($51
billion) which are 40% of the total costs. This demonstrates
both the long chronicity of these diseases, whose major
treatment is with medications, as well as the severity of the
disease in its later stages which leads to hospitalizations
with respiratory failure, pneumonia, pneumothorax and cor
pulmonale.
The disease specific cost calculations demonstrate the
wide variation in costs between chronic bronchitis and
emphysema. The higher total costs of chronic bronchitis are
due primarily to its higher prevalence, while the higher per
patient costs of emphysema, especially for hospitalization
and home care, demonstrate the greater severity of this
disease. These dierences are lost when costs are calculated
for respiratory diseases as a whole, as has been done in
most of the cost literature. Disease specific cost studies are
valuable for understanding where the major cost burden lies
for each disease.
This paper demonstrates the predominance of hospitali-
zations and medications in the care of COPD patients.
Medications were the second largest cost category, yet the
high costs of medications for COPD treatment has not been
demonstrated previously with most studies of cost not
providing detailed estimates of drug cost. The medication
estimates made in this paper were based on resource use
profiles of drug use by disease severity and type of drug.
Aggregate data on actual drug use should be examined to
validate our estimates, but available national data are too
old (NMES) or incomplete (NAMCS). To validate our
medication profiles, we examined the Scott and Levin
PDDA physician audit data on prescriptions written for
diagnoses of emphysema and chronic bronchitis. The
PDDA data are very similar to the IMS Corporations
National Disease Therapeutic Index (NDTI) data but are
collected slightly more frequently and have a refill variable.
These data do not provide information on the time a person
is on each drug for each prescription and thus are not
directly comparable to our model. However, it appears that
the relative use of the major drug categories were similar to
our model. The Scott and Levin data indicated that there
may be less drug use overall than our data demonstrate
because, for example, there were only 1 270 000 prescrip-
tions annually for emphysema drugs. If this prescription
number is applied to our prevalence data for emphysema
(2.1 million), then there is just over one prescriptionannually for every two people with the disease. This seems
quite low. As with much of the existing prescription based
drug data bases, these data are limited due to dierences in
ICD-9 definitions (using only first diagnosis for physician
visit, for example, will miss many prescriptions written for
these patients with a related diagnosis and emphysema).
Further, the Scott and Levin data consist of only physician
visit prescriptions which could exclude refills, use of mail
order pharmacies, and visits to other physicians. All of
these potential limitations may cause these types of data to
seriously under-count drugs, especially for chronic diseases.
Therefore, modeled data such as ours may be a better
estimate of average actual drug utilization per patient. We
recommend that more attention be paid to medication cost
estimates in general, in cost of illness studies. Much of the
high drug cost burden for elderly patients on Medicare may
fall on the patients themselves since Medicare generally
does not cover drugs. Until drug data bases are more widely
available, micro-costing estimates could be made based on
resource use profiles such as those provided here, especially
for diseases where drugs are the major focus of treatment.
These estimates can then be validated for parts of the
population with single institution patient surveys or
managed care data bases, when available.
Hospitalizations are the highest category of cost. Better
treatments and or disease management programs may be
able to reduce these hospitalizations as the high cost of
hospitalization combined with the low use of home care
suggests a potential to shift costs out of the hospital to the
home with better patient management. The low use of
home care is surprising in a disease where rehabilitation
programs and healthy lifestyle are an important part of
treatment and where drug compliance is low. It has
been demonstrated that home care can reduce the initial
LOS of inpatients greater than 65 years old by 34 days
and clinic visits by 62 days per patient (5). Increasing home
care or other outpatient treatment programs may improve
drug compliance, help decrease smoking and promote
respiratory and physical fitness. Although the low use of
home healthcare may be a problem with diagnosis coding,
it may also signify that more attention could be paid to
disease management in the home in an eort to improve
patients clinical condition and reduce the need for
hospitalizations.
This study has several limitations, primarily due to biases
inherent in the use of secondary data bases and the use of
modeling. Prevalences derived from the NHIS data base are
subject to response bias to the extent that patients under- or
over-report symptoms in response to open ended questions,
or the frequency with which coders miscode diseases into
appropriate ICD-9s. A study which estimates probabilities
of response bias in the NHIS demonstrated that elderly
tend to underestimate their illness and that the chronic
diseases were generally under coded (16).
Comorbidities also pose a significant problem in making
estimates of chronic disease costs from secondary data
bases. It is standard practice to make some adjustment
downward to account for multiple diseases but the factor of
adjustment for each disease has not been determined. In
this study, we attempted to adjust for comorbidities by
212 L. WILSON ET AL.careful selection of patients from the data sets and
definitions for inclusion. This will maximize our accuracy
but also omits other respiratory ICD-9s which may have a
component of chronic bronchitis.
We were also limited in estimating disease specific costs
in some cases where the sample size was too low to provide
reliable estimates and in cases where there was data only for
COPD resource use, which was then assumed to apply to
both chronic bronchitis and emphysema. Finally, there
were some areas for which there were no reliable data
available to us. We attempted to include these categories of
resource use, by combining information from expert
clinicians (for medications) and proportional estimates
available for either COPD as a whole or by using chronic
bronchitis estimates for emphysema (for home health and
nursing home care) to better reflect population based
estimates. Although we recognize that medication resource
use models are estimates and do not represent all patients,
we do not intend this as a recommended treatment. Instead
we tried to capture average treatment patterns currently in
use. We used sensitivity analysis to estimate both lower and
higher estimates of all variables to partially account for
these uncertainties. We have presented a conservative
estimate of costs and our sensitivity ranges can further
bound the base case estimates.
In conclusion, chronic bronchitis and emphysema pose a
significant cost burden to society. Hospitalizations and
medication costs account for most of the costs. Per patient
costs demonstrate the higher disease severity of emphysema
patients and the higher volume related costs associated with
chronic bronchitis. This paper provides a method for
estimating drug costs based on a micro-costing approach
using a medication resource use profile which may be
preferable to the secondary data sources used in most other
cost of illness studies which estimate costs based on non-
disease specific sales figures or incomplete physician oce
based prescription estimates. Models are frequently used to
make estimates in cost studies when other data are
unavailable (10–14). The low rates of home care may be a
signal that these patients are not receiving enough
preventative care.
Much attention has been focused by clinicians in
managed care organizations on the treatment of asthma
to increase quality of care and decrease costly emergency
visits and hospital admissions (43–45). The same attention
has not been focused on COPD. We suggest the initiation
of disease management protocols which would focus on
COPD chronic disease management in the home; including
smoking cessation programs, and medication assessment
and compliance programs. As has been seen with asthma,
such interventions may shift care and costs of COPD from
the hospital to home.
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